Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Olaparib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Multiple Cancer Types

This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have spread to other places in the body (advanced) and have come back (relapsed) or do not respond to treatment (refractory). Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Germ Cell (Pediatrics), Miscellaneous, Neuroblastoma (Pediatrics), Pediatric Lymphoma, Pediatric Solid Tumors, Pediatrics, Wilms / Other Kidney (Pediatrics)
II
Borinstein, Scott
NCT03233204
COGAPEC1621H

Olaparib with or without Atezolizumab in Treating Patients with Locally Advanced Unresectable or Metastatic Non-HER2-Positive Breast Cancer

Breast

This randomized phase II trial studies how well olaparib with or without atezolizumab work in treating patients with non-HER2-positive breast cancer that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection (locally advanced unresectable) or has spread to other places in the body (metastatic). Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. It is not known whether giving olaparib with or without atezolizumab will work better in patients with non-HER2-positive breast cancer.
Breast
II
Abramson, Vandana
NCT02849496
VICCBRE1727ET-CT

Efficacy and Safety of Olaparib, Olaparib + Bevacizumab Compared to Bevacizumab + 5-Fluorouracil (FU)

Multiple Cancer Types

This is an efficacy and safety study of olaparib alone or in combination with bevacizumab being compared to bevacizumab with Fluorouracil (5-FU) in participants with unresectable or metastatic colorectal cancer (CRC) who have not progressed following first-line induction of FOLFOX with bevacizumab. Hypothesis 1 - Olaparib + Bevacizumab is superior to 5-FU + Bevacizumab with respect to progression-free survival (PFS) using Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) in the treatment of CRC. Hypothesis 2 - Olaparib is superior to 5-FU + Bevacizumab with respect to PFS using RECIST 1.1 as assessed by BICR) in the treatment of CRC.
Colon, Rectal
III
Ciombor, Kristen
NCT04456699
VICCGI1993

Olaparib in Treating Patients with Advanced Glioma, Cholangiocarcinoma, or Solid Tumors with IDH1 or IDH2 Mutations

Miscellaneous

This phase II trial studies how well olaparib works in treating patients with glioma, cholangiocarcinoma, or solid tumors with IDH1 or IDH2 mutations that have spread to other places in the body (metastatic) and usually cannot be cured or controlled with treatment (refractory). Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Miscellaneous
II
Davis, Elizabeth
NCT03212274
VICCMD18129ET-CT

Olaparib and Entinostat in Treating Patients with Recurrent, Platinum-Refractory or Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

Multiple Cancer Types

This phase I / II trial studies the side effects and best dose of olaparib and entinostat and to see how well they work in treating patients with ovarian, primary peritoneal, or fallopian tube cancers that have come back or do not respond to platinum-based chemotherapy. Tumor samples from patients will be tested for a specific change in their genetic materials (DNA) called homologous recombination deficiency (HRD). Patients who lack this genetic change will be eligible to participate in this study. Olaparib and entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gynecologic, Ovarian
I/II
Crispens, Marta
NCT03924245
VICCGYN1842

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: